
Australians who live with a high risk of recurrence after early breast cancer will soon pay as little as $7.70 for an expanded treatment that could halt the disease from spreading.
The federal government is expanding subsidies for abemaciclib (Verzenio) for an additional 2400 Australians living with early stage breast cancer that has not yet spread beyond the area but has a high risk of doing so.